Cart
sales@molnova.com
Paltimatrectinib
CAS No. 2353522-15-1
Paltimatrectinib( —— )
Catalog No. M35642 CAS No. 2353522-15-1
Paltimatrectinib (PBI-200) is a potent tyrosine kinase inhibitor with anticancer activity that inhibits myosin-related kinase A (TrkA).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 302 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePaltimatrectinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionPaltimatrectinib (PBI-200) is a potent tyrosine kinase inhibitor with anticancer activity that inhibits myosin-related kinase A (TrkA).
-
DescriptionPaltimatrectinib (compound I-147) is a potent tyrosine kinase inhibitor with an IC50 of <10 nM for tropomyosin kinases A (TrkA). Paltimatrectinib has the potential for cancer and inflammatory diseases.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayProteasome/Ubiquitin
-
TargetTyrosinase
-
RecptorTyrosine Kinases | Trk receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2353522-15-1
-
Formula Weight434.37
-
Molecular FormulaC20H15F5N6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (57.55 mM; ultrasonic and warming and heat to 75°C)
-
SMILES[H][C@@]1(CCCN1c1ccn2ncc(-n3cc(cn3)C(F)(F)F)c2n1)c1cc(F)ccc1F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kollol Pal, et al. 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer. WO2019118584A1.
molnova catalog
related products
-
ethyl rosmarinate
Methyl rosmarinate inhibit the activity of tyrosinase, α-glucosidase, and matrix metalloproteinase-1 (MMP-1).
-
SU 5616
SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.
-
KN-93
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase.
